Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Saturday. The firm set a “hold” rating on the medical research company’s stock.

Several other brokerages have also recently issued reports on CTSO. EF Hutton Acquisition Co. I upgraded Cytosorbents to a “strong-buy” rating in a report on Monday, July 29th. HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a research report on Wednesday, August 14th.

Cytosorbents Stock Performance

Shares of CTSO stock opened at $1.00 on Friday. The stock has a market cap of $54.43 million, a PE ratio of -1.89 and a beta of 0.51. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $2.15. The business has a 50-day simple moving average of $1.15 and a 200-day simple moving average of $1.00. The company has a quick ratio of 1.71, a current ratio of 2.12 and a debt-to-equity ratio of 0.82.

Cytosorbents (NASDAQ:CTSO) last posted its earnings results on Tuesday, August 13th. The medical research company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. The firm had revenue of $9.89 million for the quarter, compared to analysts’ expectations of $9.73 million. Cytosorbents had a negative return on equity of 131.84% and a negative net margin of 68.70%. During the same period last year, the firm earned ($0.14) EPS. On average, equities analysts expect that Cytosorbents will post -0.31 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CTSO. CM Management LLC grew its holdings in shares of Cytosorbents by 98.8% during the first quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock worth $784,000 after buying an additional 410,000 shares during the last quarter. Avenir Corp grew its stake in shares of Cytosorbents by 4.0% in the 1st quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock valued at $3,014,000 after purchasing an additional 121,294 shares during the last quarter. Sargent Investment Group LLC increased its holdings in shares of Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares during the period. Finally, Atomi Financial Group Inc. purchased a new stake in shares of Cytosorbents during the third quarter worth approximately $51,000. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.